Topic Listing for Cubist Pharmaceuticals

Ability Generate Future Revenues Drug Products Successfully Develop Ability Grow Revenues Commercialization Sale Cubicin Limited Not
Acceleration Acceleration Exercisability Options
Acceleration Notes Acceleration Options
Acceptance Medical Community Accepted Agreed
Access Chiron Data Access Facility Cubists Right Monitor
Account Level Reporting Accounting Impairment Disposal Long-lived Assets
Accounting Principles Accounting Stock Based Compensation
Accounting Stock Issued Employees Accounting Stock-based Compensation
Accounting Stock-based Compensation Transition Disclosures Accounting Tax Considerations
Accounts Formulary Approvals Accounts Receivable
Accrued Clinical Research Costs Accrued Clinical Trial Expense
Accrued Liabilities Acknowledgments Return Date
Acquisition Illumigen Acquisition Illumigen Biosciences Inc
Acs Dobfar Acsd Capital Investment
Acsd Indemnification Action Consent
Active Trading Market Convertible Notes Not Develop Then Actual Award
Add Supply Chain Capacity 1h05 Addition Forward-looking Statements Represent Cubists Views Only Today
Additional Daptomycin Product Additional Officers
Additional Representations Warranties Alnylam Represents Warrants Cubist Additional Transfer Exchange Requirements
Address Adjustment Applicable Conversion Rate Fundamental Change
Adjustment Corporate Actions Adjustments
Adjustments Necessary Party Payments Royalty Territory Administration
Adoption Approval Amendment Amended Restated 2000 Equity Incentive Adverse Event Reporting Other Regulatory Matters
Adverse Interpretation Other Agreements Adverse Outcome Secs Investigation Trading Common Stock Around
Adverse Outcome Securities Exchange Commissions Investigation Trading Common Advertising Costs
Affect Relative Rights Securityholders Creditors Other Relation Holders Affiliate
Affiliate Cubist Hired Using Own Recruiting Hiring Standards Affiliates Sublicenses
Agency Means Governmental Regulatory Authority Territory Aggregated Option Exercises Last Year-end Values
Agreement Agreement Including Activities Alnylam Asian Partner Respect Development
Agreement Subordinate Agreement Subordinate Unaffected
Agreement Terminated Astrazeneca Pursuant Following Clauses Agreement Terminated Cubist Pursuant Following Clauses
Agreement Terminated Either Party Pursuant Following Clauses Agreements Material Provisions
Albany Alliance Managers
Aln-rsv Compounds Aln-rsv Program
Alnylam Collaboration Agreement Alnylam Cubist Announce Complete Data Phase Study Aln-rsv01
Alnylam Forward-looking Statement Alnylam Forward-looking Statements
Alnylam Grants Alnylam Pharmaceuticals
Alnylam Sequence Specific Know-how Means Rsv01 Product Other Amendment
Amendment Code Ethics Amendment Development Supply Agreement
Amendment Effective Date Amendment Exhibits Addition New
Amendment Loan Security Agreement Amendment Waiver
Amendments Amendments Articles Incorporation Bylaws Change
Amino Acid Sequence Dx-88 Annual Amount Due Meaning Ascribed Such Term
Annual Base Salary Annual Meeting
Annual Performance Awards Annual Performance Bonus Awards
Annual Quarterly Baseline Sales Example Calculation Amount Due Annual Report Form 10-k
Anonymously Antibacterial Agents Serious Infections
Antibiotic Agents Serious Infections Antibiotic Candidates Now Phase
Antiviral Therapy Hepatitis Virus Hcv Infections Api Bulk Drug Substance Means Licensed Product
Applicability Chiron Patents Applicable Supply Agreement Provisions
Application Trust Money Approved Fda
Arbitration Arbitration Dispute Not Resolved Pursuant 141 Above Then
Archer Assignment
Assignment Chiron Assignment Cubist
Assignment Form Assistant Secretary
Assistant Treasurer Associated Press
Astrazeneca Astrazeneca Csd Materials Meaning Ascribed Such Term
Astrazeneca Merrem Registered Trademarks Group Companies Astrazeneca Shall Notify Writing Cubist Promptly Practicable Occurrence
Astrazenecas Broad Spectrum Antibiotic Merrem Attempting Resolve Disputes Relating Commercialization Licensed Product Territory
Audit Committee Audits Each Party Shall Keep Complete Accurate
Aureu Aureus
Aureus Endocarditis Bacteremia Trial Aureus Mrsa
Authority Binding Agreement Authorization Effect Subordination
Authorization Enforceability Authorized Disclosure Notwithstanding Other Provision Agreement Each Party
Authorized Signatures- Completed Vote Counted- Date Sign Below Authorized Signatures-this Completed Vote Counted-date Sign Below
Automatic Grants Available
Average Daily Cubicin Net Product Sales Per Shipping Avoidance Infringement
Award B-1
Background Background Purpose
Bactericidal Bacteriostatic
Bank New York Trust Trustee Base Salary
Baseline Commencement Date Shall Mean Basic Diluted Net Loss Per Common Share
Basis Presentation Basis Presentation Consolidation
Basis Pro Forma Presentation Batch Record
Bate Bbbbb Program Commencement Date Means 2008
Become Involved Patent Litigation Other Intellectual Property Proceedings Beneficial Ownership Reporting Compliance
Bicin Commercialization Bist News
Black Diamond Research Blood Stream Infections Infective Endocarditis Caused Aureus
Board Directors Committees Board Directors Recommends Stockholders Vote Nominees Director Proposal
Board Directors Recommends Stockholders Vote Proposal Board Directors Recommends Vote Nominees Listed Proposals
Board Recommends Stockholders Vote Proposal Board Room Main
Bonney Borrowing Procedures
Business Business Agreements
Business Negatively Affected Result Actions Activist Shareholders Business Policies Means
Business Segment Geographical Information Business Segments
Business Suffer Fail Manage Growth Effectively Business Suffer Fail Manage Growth Increased Breadth Activities
Business Suffer Management Uses Proceeds Offering Ineffectively Calculating Actual Awards
Calculating Amount Target Award Calculation Actual Plan Award
Calculation Payment Fees Cubist Calculation Portion Tied Individual Results
Calculation Portion Tied Results Calendar Net Sales Rsv01 Product Equal Royalty Payable
Calixa Cambridge
Cambridge Mass Lexington 2009 Cancellation
Cancellation Converted Securities Capital Lease Obligations
Capital Leases Cardinal Health Inventions
Cardinal Healths Biotechnology Sterile Life Sciences Facility Cash Equivalents
Cashless Exercise Cb-182804
Cb-182804 Infections Caused Gram-negative Bacteria Cb-182804 Pre-ind Candidate Intravenous Antibiotic Serious Infections Caused
Cb-183315 Cb-183315 Infections Caused Clostridium Difficile Bacteria
Cb-183315 Pre-ind Candidate Oral Antibiotic Treatment Difficile Associated Cb-183872 Infections Caused Hepatitis Virus
Cb-183872-pre-clinical Candidate Novel Antiviral Agent Treatment Hepatitis Virus Cb-500929 Ecallantide
Ccc Escalation Period Meaning Ascribed Such Term 161 Cccccc Term Meaning Ascribed Such 151
Cdad Ceo Compensation Determination Process
Certain Conversions Deemed Payment Certain Definitions
Certain Relationships Related Transactions Certain Relationships Related Transactions Director Independence
Certificate Amendment Restated Incorporation Cubist Pharmaceuticals Inc Pursuant Certificate Analysis Coa
Certificates Analysis Certification
Certification Pursuant Usc 1350 Adopted 906 Sarbanes-oxley Act Cgmp
Cgmps Chairman Lead Director Board
Change Control Change Control Means Respect Party Event
Change Procedures Changed Purchase Orders
Changes Current Anticipated Market Demand Medical Need Cubicin Changes Eligibility
Changes Specifications Process Charter
Checks Drafts Notes Chiron
Chiron Compliance Chiron Cubist Data
Chiron Development Plan Chiron Joint Technology Rights Shall Mean Chirons Right
Chiron Know-how Chiron Partnership
Chiron Patent Chiron Patents
Chiron Related Know-how Chiron Related Patent
Chiron Representation Warranty Intellectual Property Claims Related Intellectual Property
Clinical Development Cubicin Clinical Supplies
Clinical Trials Clinical Trials Drug Candidates Unsuccessful Delayed Unable Meet
Clinicians Now Consider Mrsa Potential Pathogen Patients Suspected Clostridium Difficile
Cmc Means Chemistry Manufacturing Controls Ind Nda Co-promotion Rights
Code Conduct Ethics Code Ethics
Coli Acinetobacter Collaboration Guidelines
Collaboration Party Technology Included Definition Cubist After Effective Collaborative Agreement Other Revenues
Collaborative Other Similar Types Relationships Expose Number Risks Collaborative Relationships Expose Number Risks
Collection Suit Trustee Combined Consolidated Financial Statements
Commercial Launch Commercialization Agreements
Commercialization Certain Other Responsibilities Commercialization Costs Each Case Determined Books Records Applicable
Commercialization Plan Commercialize
Commercially Important Indications Commercially Reasonable Efforts
Commitments Commitments Contingencies
Committee Committee Authority Responsibilities
Common Stock Common Stock Reserved Future Issuance
Common Stock Shares Reserved Communications
Communications Holders Other Communications Meeting Minutes Respect Such Clarity Cubist Exclude
Communications Relating Development Communications Relating Regulatory Approval
Compensation 2004 2005 Compensation 2005 2006
Compensation Benchmarking Compensation Benchmarking Survey Data
Compensation Committee Compensation Committee Interlocks Insider Participation
Compensation Committee Report Compensation Directors
Compensation Discussion Analysis Compensation Elements Targeted Market Levels
Compensation Indemnity Compensation Objectives
Compensation Philosophy Compensation Philosophy Objectives
Compensatory Arrangements Certain Officers Competition
Competition Fair Dealing Competition Step-down
Competitors Develop Drug Products Make Obsolete Competitors Develop Drug Products Make Obsolete Less Cost
Complete Satisfaction Completely Dependent Parties Manufacture Cubicin Commercialization Stopped Delayed
Completion Acquisition Disposition Assets Compliance Certificates
Compliance Laws Compliance Laws Rules Regulations
Compliance Procedures Compliance Securities Laws Purchase
Compliance Trust Indenture Act Comprehensive Income
Comprehensive Income Loss Comprehensive Loss
Comycin Concentration Credit Risk
Concentration Risk Conclusion
Conclusion Regarding Effectiveness Disclosure Controls Procedures Conclusions
Conference Call Webcast Information Conference Call Webcast Information Cubist Host Live Audio
Conference Room-first Office Confidential
Confidential Information Confidential Treatment Processing Services Agreement
Confidential Treatment Requested Omitted Portions Filed Confidential Treatment Requested Omitted Portions Filed Separately
Confidentiality Confidentiality Publicity
Conflict Conflict Inconsistency
Conflict Interest Conflicts Interest
Consent Ernst Young Llp Independent Auditors Consent Holders
Consent Independent Auditors Consent Independent Registered Public Accounting Firm
Consent Independent Valuation Firm Consents
Consequences Termination Consolidate Etc Only Certain Terms
Consolidated Financial Statements Statement Schedule Contacts
Context Capital Continuing Obligations
Contract Contract Employment
Contract Manufacturing Agreements Contractor
Contractual Obligations Control
Control Majority Controls Procedures
Conversion Conversion Consideration
Conversion Notice Conversion Procedure
Conversion Right Convertible Notes
Convertible Notes Stockholders Equity Convertible Notes Unsecured Contain Restrictive Covenants
Convertible Preferred Stock Convertible Subordinated Notes Due 2013
Cooperation Corporate Compliance Program Cannot Ensure Applicable
Corporate Compliance Program Cannot Ensure Applicable Fraud Abuse Corporate Compliance Program Cannot Ensure Applicable Laws Regulations
Corporate Existence Power Corporate Goal Setting Compensation Purposes
Corporate Goals Corporate Governance Guidelines
Corporate Governance Nominating Committee Corporate Opportunities
Corporate Overview Business Strategy Corporate Performance Graph
Cost Guidance Cost Product Revenues
Costs Expenses Count Ordering Trends
Counterparts Credit Facility
Critical Accounting Policies Estimates Critical Accounting Policies Significant Judgments Estimates
Critical Equipment Csd Activities
Csd Materials Meaning Ascribed Such Term Cub Icin Guidance
Cubicin Cubicin Daptomycin Injection
Cubicin Guidance Cubicin Market
Cubicin Net Product Revenues 1201 Cubicin Not Yet Approved Fail Fulfill Certain Post-approval
Cubicles 8x8 Wired Electric Data Cubist
Cubist Api Bulk Drug Substance Finished Product Alnylam Cubist Building Enduring Model
Cubist Csd Materials Meaning Ascribed Such Term Cubist Data
Cubist Development Plan Cubist Expanded Sales Force
Cubist Forward-looking Statement Cubist Grants
Cubist Inventions Cubist Investment
Cubist Know-how Cubist Knowledge Group Means
Cubist Marks Cubist Patent
Cubist Patents Cubist Pharmaceuticals
Cubist Pharmaceuticals Acquire Calixa Therapeutics Cubist Pharmaceuticals Inc
Cubist Pharmaceuticals Inc Computation Pro Forma Ratio Earnings Cubist Pharmaceuticals Inc Computation Ratio Earnings Fixed Charges
Cubist Pharmaceuticals Inc Hayden Avenue Lexington 02421 Notice Cubist Pharmaceuticals Inc Index Consolidated Financial Statements Schedule
Cubist Pharmaceuticals Inc Valuation Qualifying Accounts Reserves 2004 Cubist Pharmaceuticals Reports 2006 Results
Cubist Providing Information Date News Release Not Undertake Cubist Representation Regarding In-licenses Represents Effective Date
Cubist Representative Cubist Represents Warrants Effective Date Covenants Astrazeneca
Cubist Safe Harbor Statement Cubist Technology
Cubist Technology Licensed Parties Cubist Technology Means Collectively Know-how Patent Rights
Cubist Technology Shall Mean Patents Know-how Cubists Improving Balance Sheet
Cubists Landmark Aureus Bacteremia Endocarditis Trial Cumulative Gross Sales Since Launch Ics Cubicin Ims
Current Credit Financial Market Conditions Exacerbate Certain Risks Current Portfolio
Current Report Pursuant Securities Exchange Act 1934 Cusip Numbers
Cxa-201 Daptomycin
Daptomycin Product Daptomycin Standard Therapy Staphylococcus Aureus Bacteremia Sab Infective
Date Adjustments Dated 2008
David Mcgirr Chief Financial Officer Senior Vice President David Mcgirr Cubist Cfo
David Munno Merrill Lynch Dddddd
Deal Signed Initiating Partnership Debarred Personnel
Debt Decision License Party Technology
Deductions Tax Withholding Default Designated Senior Indebtedness
Defense Deferred Taxes Valuation Allowance
Defined Terms Used Not Herein Shall Respective Meanings Definitions
Definitive Delay Purchases Payment Product Price Premiums
Delivery Demonstrated Vitro Clinical Relevance Data Not Been Established
Departure Directors Certain Officers Election Appointment Compensatory Departure Directors Certain Officers Election Appointment Compensatory Arrangements
Departure Directors Principal Officers Election Appointment Departure Termination
Depend Heavily Success Lead Product Cubicin Not Continue Depend Heavily Success Lead Product Cubicin Not Widely
Depend Parties Conduct Clinical Trials Cubicin Drug Candidates Depend Parties Conduct Clinical Trials Cubicin Ecallantide Expect
Depend Parties Conduct Clinical Trials Cubicin Expect Respect Depend Parties Conduct Clinical Trials Cubicin Hepex-b Expect
Deposit Redemption Price Description Business
Designated Medical Affairs Representatives Desire Intent Make Certain Fully Understand Provisions Effects
Determination Relative Financial Benefits Determined Cubist
Determining Fair Value Volume Level Activity Asset Liability Development Efforts Manner Performance Records Reports
Development Licensed Products Additional Rsv Opt-out Rights Development Milestone Payments
Development Plan Amendments Responsibilities Deviation
Directions 2008 Annual Meeting Stockholders Cubist Pharmaceuticals Inc Directly Competitive Product
Director Benefits Director Compensation
Director Independence Director Nomination Process
Director Qualifications Directors Executive Officers Corporate Governance
Directors Executive Officers Registrant Disclaimer
Disclosing Party Means Confidential Information Disclosure Schedule
Disclosures Segments Enterprise Related Information Discounting
Discovery Research Generation Lipopeptide Daptomycin Lung Activity Discrimination Harassment
Dispute Resolution Disputes
Dissolution Liquidation Distribution Notice Representative
Distribution Paid Over Dividends
Dmf Means Drug Master Filed Fda Equivalent Documents Incorporated Reference Portions Registrants Definitive Proxy Statement
Drug Approval Application Drug Master
Drug Master Dmf Duties Trustee
Dx-88 Surgery Dyax
Dyax Clinical Trials Dyax Disclaimer
Each Officers Certificate Opinion Counsel Respect Compliance Condition Each Party Represents Warrants Other Effective Date Follows
Each Party Shall Comply Applicable Law Connection Collection Each Party Shall Times Responsible Performance Sublicensees Agreement
Ease Ecallantide
Ecallantide Cts Ecallantide Phase Trials Proceeding Smoothly
Ecallantide Prevention Bleeding Cardio-thoracic Surgery Ected Balance Sheet
Effect Departure Effect Notice Redemption
Effect Supplemental Indentures Effect Termination
Effective Date Party Licenses Effective Tax Rate
Effectiveness Effectiveness Committee
Efficacy Pneumoniae Lung Infection Mice Efforts Require Asian Partner Become Party Safety Information
Eisenstein Elections
Elements Compensation Eli Lilly
Eligibility Eligibility Disqualification
Eligibility Participation Eligible Director
Eline Email Copies
Emea Emea Means European Medicines Agency Successor Thereto
Emea Process Employee Benefits
Employee Release Employee Stock Purchase Plan
Employees Employees Promptly Report Violations Suspected Code Illegal Activities
Employment Changes Employment Contracts Termination Change-in-control Arrangements
Ending Engagement
Enrollment Phase Endocarditis Bacteremia Trial Complete Enrollment Treatment Follow-up Complete
Enterococcus Faecalis Entire Agreement
Entire Agreement Amendment Entry Material Definitive Agreement
Equitable Remedies Injunctive Relief Equity Acceleration
Equity Compensation Plans Equity Contribution
Equity Granting Practices Erage Daily Cubicin Net Product Sales
Escrow Shares Estimates
Etc Etration Formulary Approvals
Eun Yang Jeffries European Union-emea Process
Event Events Default
Every Provision Indenture Way Relates Trustee Subject Subsections Exact Name Registrant Specified Charter
Exact Stock Price Effective Date Fundamental Change Not Exceeded Goal Registering 700 Cases 2004
Except Continuance Event Default Exclusivity
Execution Authentication Executive Committee
Executive Compensation Executive Compensation Proposal 1-election Directors Corporate Performance Graph
Executive Officer Compensation Determination Process Other Ceo Executive Summary
Exercise Administrative Executive Judicial Legislative Police Regulatory Taxing Exercise Cash
Exercise Option Exercise Stock
Exhibits Existing Agreements Financial Obligations
Existing Dyax Patent Rights Existing Dyax Patent Rights Filed Due New Rules
Existing Related Intellectual Property Chiron Expand Label Cubicin Approved
Explanatory Exports Licensed Product Territory
Exposed Potential Risks Legislation Requiring Companies Evaluate Controls Exposed Potential Risks Recent Legislation Requiring Companies Evaluate
Extent Required Applicable Law Cubist Shall Ensure Representatives Face Significant Competition Other Biotechnology Pharmaceutical Companies Particularly
Facility Facility Approval Target Date
Facility Completion Facility Completion Target Date
Failure Comply Such Regulations Prevail Litigation Related Noncompliance Failure Cure
Fair Value Financial Instruments Fca
Fda Fda Change Approval Requirements Policies Antibiotics Apply Interpretations
Fda Orange Book Fda Process
Fda Shall Mean United States Food Drug Administration Federal Gift Estate Tax Consequences Transfers
Federal Income Tax Aspects Espp Federal Tax Consequences Cubist Award Recipient
Federal Tax Consequences Cubist Recipient Option Stock Grants Fees Incurred Connection Filings Relating Regulatory Approvals Pricing
Fellows Fetzer
Ffff Ndc Means National Drug Code Field
Field Means Treatment Prophylaxis Diseases Humans Figure Actual Sti Plan Award Calculation Examples
Figure Portions Tied Individual Results Figure Target Award Calculation Examples
Figure Target Percentage Level Fin 48-uncertain Tax Positions
Final Decision-making Dispute Resolution Financial Measures
Financial Statement Schedule Financial Statements
Financial Statements Business Acquired Financial Statements Exhibits
Financing Activities Find Information
Flagship Product Cubicin Force Majeure
Foreign Currency Foreign Currency Translation
Foreign Exchange Forfeiture Shares
Form 10-k Form 10-q
Form Dating Form Face Security
Form Joint Press Release Formal Investigation
Formation Formulary Acceptance Rate Still Above Expectations
Forward Contracts Forward-looking Statements
Forward-looking Statements Speak Only Date Release Cubist Undertakes Fractional Share Interests
Fractional Shares Francis Tally Svp Chief Scientific Officer
François Vandenesch Timothy Naimi134 Enright135 Gerard Lina Graeme Full Highlights
Funding Furnish
Further Further Actions
Further Assurances Further Instruments Acts
G-1 Cubist Trademarks G-2 Astrazeneca Housemarks
General General Administrative Expense
General Administrative Expenses General Option Information
General Permanent Conditions General Powers
Generally Generally Available Parties Disclosing Party Affiliates Without Restriction
Generic Primaxin Introduced Expiration Mercks Patents 2009 Ggg Means Respect Period Net Sales Such Less
Gisa Visa Glycopeptide- Vancomycin-intermediately Susceptible Aureus Global Database
Goal Setting Compensation Purposes Good Basis Deciding Get Advice Ask Whether Conduct
Good Basis Deciding Get Advice Ask Yourself Whether Good Manufacturing Practices
Governance Committee Governing Law
Governing Law Judicial Resolution Government Order Means Writ Judgment Injunction Decree
Government Regulation Governmental Inspections
Grant Exercise Options Price Grant Lapse Restrictions
Grants Growth Within Existing Added Target Accounts Since Sales
Grégoire Guarantees
Guarantees Indemnification Obligations Guaranty
Guiffre H06
Harris Nesbitt Hatch-waxman Act
Hayden Avenue Lexington Massachusetts 02421 Hazardous Materials Chemicals Microorganisms Radioactive Compounds Exposes Potential
Hazardous Materials Chemicals Viruses Radioactive Compounds Exposes Potential Hcv
Headings Health Safety
Hhhhhh Trademark Means Trade Dress Brand Name Corporate Hierarchy Generally Accepted Accounting Principles Replacement Fasb Statement
Highlights Hoc
Hold Convertible Notes Not Entitled Rights Respect Common Holder
Holders Hostile Change Corporate Control
However Ib657
Ich Means International Conference Harmonization Technical Requirements Icin Commercialization
Icin International Commercialization Ids Ranked Cubicin Ahead Vancomycin Zyvox Attributes
Iii- Promotion Other Services Iiii Nurse In-service Means
Iiiii Quarterly Baseline Sales Meaning Ascribed Such Term Illumigen
Impact Accounting Tax Form Compensation Impact Adoption Sfas 123
Impairment Long-lived Assets Implemented Anti-takeover Provisions Discourage Prevent Delay Takeover Even
Important Annual Stockholders Meeting Information Vote Counts Important Notice Regarding Internet Availability Proxy Materials 2008
In-licensing Programs In-process Specifications
In-process Testing Procedures Specifications Income Tax Expense Benefit
Income Taxes Incumbent Directors
Incur Liabilities Tax Authorities Excess Amounts Been Accrued Incur Substantial Costs Resulting Product Liability Claims Relating
Incurred Substantial Losses Past Expect Incur Additional Incurred Substantial Losses Past Expect Incur Additional Over
Incurred Substantial Losses Past Incur Additional Indebtedness Restrictions Imposed Terms Debt Adversely Affect Financial
Indemnification Indemnification Chiron
Indemnification Cubist Indemnification Employees Agents Corporation
Independence Independent Auditors Report
Independent Contractor Status Cubist Including Sales Force Csd Independent Contractors
Independent Public Accountants Independent Registered Public Accounting Firm
Index Index Financial Statements
Indications Important Safety Information Individual Objectives
Individual Rights Trustee Inds Ndas Drug Approval Applications
Industry Highly Regulated Products Subject Ongoing Regulatory Review Infectious Disease Marketplace
Infective Endocarditis Complicated Bacteremia Caused Aureus Information
Information Directors Nominees Director Information Sharing
Infringement Chiron Patents Joint Outside Territory Infringement Patents Territory
Infringement Trademarks Parties Initial 2005 Quantity
Initial 2006 Quantity Initial Product Sales Training Plan Cubist
Initial Sales Training Materials Injunctive Relief
Inpatient Insider Trading
Inspection Inspection Books
Inspectors Insurance
Intangible Assets Intellectual Property
Intellectual Property Ownership Protection Related Matters Intellectual Property Portfolio
Intentionally Omitted Interest
Interest Convertible Notes Not Fully Deductible Federal Income Interest Expense
Interest Income Interest Income Expense
Interim Disclosures Fair Value Financial Instruments Interim Financial Information
Interim Financial Statements-an Amendment Apb Opinion Internal Control Over Financial Reporting
Internal Control-integrated Framework International Marketing Partners Cubicin
International Opportunity Cubicin International Partnership Chiron
International Product Revenues Intrinsic Value Unvested Stock Options
Introduction Introduction Background
Inventories Inventory
Inventory Costs Investing Activities
Investment Cash Subject Risks Result Losses Investments
Invoicing Payment Issuance Certificates
Ix- Returned Recalled Product Jason Kantor Rbc Capital Markets
Jct Coordinators Joe Slavinsky Thomas Weisel Partners
Joint Development Costs Joint Know-how
Joint Patents Joint Steering Committee Parties Hereby Establish Facilitate Collaboration
Kantor Rbc Key Development Studies Diligence Obligations
Kitchen Kkkk Other Meropenem Product Means
Kkkkk Recipients Meaning Ascribed Such Term 121 Know-how Step-down
Knowledge Alnylam Means Kyowa Hakko Means Kirin Ltd Formerly Known
Label Lapse Restrictions
Late Payments Latent Defect
Lazard Capital Lead Director
Leases Leave Absence
Legal Holidays Legal Proceedings
Level Inputs Lexington 2005
Lexington 2006 Lexington 2007
Lexington 2008 Lexington 2009
Lexington Mass 2009 Lexington Mass 2010
Lexington Mass Cambridge 2009 Lexington Mass Oct 2009
Lexington Seattle Lexington Seattle 2007
Liability Party Products Claims License Agreement
License Agreements License Agreements Commitments
License Collaboration Agreement License Fee Revenues
License Option License Revenues
Licensed Product Royalties Royalty Territory Licensed Products Shall Mean Daptomycin Additional Become Pursuant
Licenses Chiron Subject Accordance Terms Conditions Agreement Licenses Cubist Subject Terms Conditions Agreement
Licensing Agreements Licensing Collaboration Agreements
Licensing Party Technology Licensing Resolve Infringement Cubist Technology
Lilly License Limitation Activities
Limitation Chirons Development Rights Limitation Liability
Limitation Obligation Sublicense Limitation Rights Stock
Limitations Liability Limitations Suits
Limited Authority Not Decision-making Body Line Data
Liquidation Dissolution Bankruptcy Liquidation Preference
Liquidity Capital Resources List European Countries
List Exhibits Litigation
Lll Indemnifying Party Meaning Ascribed Such Term 144 Loan Security Agreement
Long-lived Assets Long-term Incentive Compensation Performance Stock Option Awards
Long-term Incentive Compensation Stock Option Awards Long-term Investments
Lost Stolen Destroyed Certificates Lot Number
Maa Maintenance Corporate Existence
Maintenance Records Major Country Means United Kingdom France Germany
Major Market Countries Management Discussion
Management Stockholders Managements Report Internal Control Over Financial Reporting
Manufacturing Compliance Reports Manufacturing Distribution Other Agreements
Manufacturing Documentation Manufacturing Information
Manufacturing Quality Manufacturing Supply Agreement
Manufacturing Supply Agreements Market Information
Market Launch Cubicin Market Opportunity Positioning Cubicin
Market Performance Cubicin Market Registrants Common Equity Related Stockholder Matters
Market Registrants Common Equity Related Stockholder Matters Issuer Marketing Activities Chiron Commercially Reasonable Efforts
Marketing Directly Competitive Product Marketing Plan
Marketing Promotional Literature Martin
Material Material Agreements Related Licensed Products Territory
Material Modification Rights Security Holders Material Review Board Mrb
Materials Matt Duffy Bdr Research
Maupay Mcgirr
Mdr Gram-negative Infections Mechanism Determine Fair Market Value
Medical Affairs Studies Medical Dental Benefits
Medicine Medison Pharma Ltd
Meeting Agendas Meeting Fees
Meetings Members Qualifications
Membership Merrem
Merrem Finished Goods Inventory Sales Methicillin-susceptible Methicillin-resistant Aureus
Method Awarding Restricted Stock Method Awarding Stock Grants
Method Exercise Options Michael Bonney Cubist Pharmaceuticals President Ceo
Michael Bonney Cubist President Ceo Michael Bonney President Ceo
Mike Milestone Payments
Milestone Payments Existing Alnylam In-licenses Milestones
Minimum Payments Royalty Territory Minus
Minute Infusion Time Misappropriation
Miscellaneous Miscellaneous Libor Rate Loan Terms
Misrepresentations False Statements Morgan Stanley
Most Successful Antibiotic Launch History Mrsa Agents Average Growth Per
Mrsa Methicillin-resistant Aureus Msyang Jeffries
Multiple Counterparts Multiple Element Arrangements
Munity Mrsa Growing Concern Munno Merrill Lynch
Name Name Each Exchange Registered
Nasdaq Global Select Market Nasdaq National Market
National Report Nature Business
Nda Nda 2003 149
Nda Manufacturing Supplement Need Obtain Regulatory Approvals Dx-88 Other Drug Candidates
Need Obtain Regulatory Approvals Other Drug Candidates Ability Neither Saturday Sunday Nor Legal Holiday Commercial Banks
Net Income Net Loss Per Common Share
Net Product Sales Net Sales
New Accounting Pronouncements New Accounting Pronouncements Guidance Require Change Way Account
New Accounting Standards New Accounts Ordering Per
New Drug Application New Hires
New Plan Benefits New York Beth Israel Deaconess Medical Center Harvard
Nolo Contendere Nomination Board Members
Nominees Election Directors Non-disparagement
Non-exclusivity Rights Non-gaap Financial Measures
Non-infringement Cubist Technology Parties Non-voting
Noncompetition Nonconforming Materials Report
Not Not Able Obtain Maintain Protect Certain Proprietary Rights
Not Corporate Entity Possession Directly Indirectly Power Direct Not Included Original Fte Cost Calculation Change Shall
Not Return Proxy Card Voting Telephone Internet Not Successful Attracting Retaining Highly Qualified Personnel Able
Not Successful Attracting Retaining Management Team Members Other Not Successful Management Transition Attracting Retaining Team Members
Notation Exchange Securities Notes Payable
Notes Receivable Related Parties Notice
Notice 2006 Annual Meeting Stockholders Notice 2007 Annual Meeting Stockholders
Notice 2008 Annual Meeting Stockholders Notice 2009 Annual Meeting Stockholders
Notice Adjustments Conversion Rate Notice Certain Corporate Transactions
Notice Default Events Notice Meeting
Notice Persons Notice Redemption
Notice Stockholder Business Nominations Notices
Notification Notwithstanding Sections Cubists Expense Respect Product
Novel Mechanism-of-action Now Therefore
Number 0-21379 Number Directors Vacancies
Number New Accounts Brought Per Holding Steady Obligation Supply
Obtaining Copy Proxy Materials Receive Paper E-mail Documents Offer Notice
Offer Space Officers Directors Certain Stockholders Choose Act Together They
Offices Ongoing Phase Study Budget
Operate Competitive Labor Market Inability Hire Retain Highly Operating Activities
Operating Expenses Operator
Oppositions Appeals Option
Option Exercises Stock Vested 2007 Option Granting Practices
Option Grants Option Grants Last
Optional Redemption Optionee
Options Options Grants
Organization Basis Presentation Oryx
Other Other Actions
Other Business Other Committees
Other Costs Incurred Explicitly Included Budgets Development Plan Other Defined Terms
Other Events Other Executive Officers
Other Expense Other Expense Net
Other Income Other Income Expense
Other Income Expense Net Other Information
Other Infringement Cubist Patents Other International Markets-drug Approval Process
Other Licensee Data Shall Mean Information Results Development Other Regulatory Processes
Other Remedies Other Representations
Other Revenues Otherwise Required Applicable Law Based Advice Legal Counsel
Ount Ordering Trends Out-of-pocket Costs Expenses Incurred
Outpatient Outside Director
Outstanding Convertible Notes Converted Shares Common Stock Existing Outstanding Securities
Overdose Sensitivity Reactions Failure Product Expected Pharmacologic Biologic Overview
Overview Infectious Diseases Drug Resistance Ownership Intellectual Property
Ownership Inventions Ownership Marketing Information
Ownership Regulatory Approvals Pacific Growth
Paid Cubist Pursuant Shall Fully Creditable Against Royalties Pamela Moise-broder George Sakoulas Eliopoulos Jerome Schentag Alan
Paragraph Certification Notice Letter Pari Passu
Part Other Information Part-time
Participants Parties Patent Rights
Partners Market Cubicin Including Marketing Approvals New Products Party Infringement
Party Means Either Alnylam Cubist Party Patent Rights
Party Payors Such Reimbursement Products Reduced Insufficient Negative Party Royalties Other Payments
Party Supply Party Technology
Patent Patent Costs
Patent Litigation Other Intellectual Property Proceedings Relating Products Patent Marking
Patent Prosecution Patent Term Extensions
Patents Know-how Paying Agent Hold Money Trust
Payment Payment Product Price Premiums
Payment Securities Payments Christopher Guiffre Assuming 2007 Termination
Payments Government Personnel Payments Lindon Fellows Assuming 2007 Termination
Payments Robert Perez Assuming 2007 Termination Penetration Formulary Approvals
Perez Performance Affiliates
Performance Periods Period
Perquisites Personal Benefits Personal Liability Directors Officers Employees Stockholders
Phase Clinical Trials Pipeline Programs
Pipeline Strategic Focus Pipeline Update
Place Meetings Place Meetings Books
Plan Plan Award Payout Process
Plan Objective Plan Overview
Please Please Vote Date Sign Proxy Other Side Return
Plus Political Activities Engagement Government Personnel
Position Iss Proposal Potential Advantages Over Current Standard Care
Powers Denied Committees Pre Clinical Testing
Pre-clinical Clinical Trials Drug Candidates Unsuccessful Delayed Unable Pre-tax Profit Loss
Preclinical Programs Preferential Collection Claims Against
Preferred Stock Prescriber Level Reporting
Prescription Drug User Fee Act Presentation
President Press Release
Press Release Contains Forward-looking Statements Including Regarding Development Press Release Contains Forward-looking Statements Regarding Trial Date
Previously Reported Filings Sec Adverse Outcome Secs Investigation Price
Price Approval Pricing Payment
Primary Daptomycin Molecule Primary Endpoint
Principal Accountant Fees Services Principal Accounting Fees Services
Priorities Pro Forma Adjustments Assumptions
Pro Forma Adjustments Balance Sheet Pro Forma Adjustments Statements Income
Pro Forma Adjustments Statements Operations Pro Forma Condensed Combined Consolidated Financial Statements
Pro Forma Financial Information Pro-rata Guidelines
Procedure Process Development Quality Systems Facility Qualification Support
Process Improvements Process Invention
Process Validation Product
Product Approval Product Competitors
Product Comply Applicable Law Business Policies Extent Consistent Product Development Pipeline
Product New Indication Approved Product Orders
Product Pipeline Product Price
Product Price Premium Product Price Premiums
Product Recalls Product Release Test Methods Specifications
Product Revenues International Distribution Partners Product Revenues Net
Product Rights Product Specifications
Product Trademarks Infringe Party Rights Product Training
Product Warehousing Payment Schedule Product Warranty
Products Pipeline Programs Products Reduced Insufficient Negative Impact Utilization
Products Subject Ongoing Regulatory Review Profit-share Territory Means Subject North America
Prohibited Marketing Sales Activities Promotion Plan
Properties Property Equipment
Proportion Aureus Nosocomial Infections Resistant Oxacillin Mrsa Among Proposal
Proposal Approval Amendment 1997 Employee Stock Purchase Plan Proposals-the Board Directors Recommends Vote Nominees Listed Proposals
Proposed Indications Proprietary Rights
Proprietary Rights Notices Prosecution Maintenance Patent Rights
Protection Proper Assets Provide Issuance Additional Securities Having Same Terms Initially
Provide Stock Provided
Provided Further Provided However
Provision Income Taxes Provisions Clauses Below Shall Apply Only Global Securities
Proxies Submitted Internet Telephone Received 200 Eastern Time Proxy Solicitation
Proxy Solicited Board Directors 2005 Annual Meeting Stockholders Proxy Solicited Board Directors 2006 Annual Meeting Stockholders
Proxy Solicited Board Directors 2007 Annual Meeting Stockholders Proxy Solicited Board Directors 2008 Annual Meeting Stockholders
Pseudomonas Aeruginosa Publications
Publicity Pullman
Pulmonary Reduction Burden Pneumoniae Infection Mice Purchase Commitment
Purchase Forecasts Purchase Investment
Purchase Options Purchase Orders
Purchase Orders Forecasts Purchase Price
Purchase Pricing Commitment Furnishing Delivery Purpose
Purpose Committee Pyogenes
Quality Documentation Facility Expectation Acceptance Quality Requirements
Quantitative Qualitative Disclosures Market Risk Quarterly Net Product Revenues
Quorum Quorum Adjournment
Rage Daily Cubicin Net Product Sales Ramagan
Ramagan Albany Rancis Tally Cubist Chief Scientific Officer
Rather Such Party Shall Cause Affiliate Commercially Diligent Ratification Adoption Approval Amended Restated 2002 Directors Equity
Ratification Appointment Independent Auditors Ratification Appointment Independent Registered Public Accounting Firm
Rating Convertible Notes Cause Trading Prices Fall Rbc Capital Markets
Reasonable Buyer Reasons Amendment
Recalls Voluntary Withdrawals Recapitalization
Recent Accounting Pronouncements Recent Accounting Standards
Recently Future Undertake Strategic Acquisitions Not Realize Benefits Recently-filed Ind Candidates
Recitals Reclassifications
Record Date Record Date Vote Consent Securityholders
Record Date Voting Rights Record-keeping
Records Records Regulatory Matters
Recoupment Policy Redemption
Reduce Percentage Aggregate Principal Amount Outstanding Securities Whose Reductions Offsets
Regions Countries Territory Registrants Telephone Number Including Area Code
Registrar Paying Agent Conversion Regular Meetings
Regulation Disclosure Regulatory Approval
Regulatory Data Affairs Regulatory Filings
Regulatory Plan Regulatory Plan Diligence Obligation
Reimbursement Development Costs Reinstatement
Related Matters Relative Rights
Release Claims Remainder Page Been Intentionally Left Blank
Remainder Page Intentionally Left Blank Remaining 2005 Quantity
Remaining 2006 Quantity Removal
Repayment Repayments Prepayments Interest
Replacement Securities Replacement Trustee
Replay Available Via Internet Wwwcubistcom Report Audit Committee
Report Chief Executive Officer Compensation Report Executive Officer Compensation
Report Illegal Unethical Behavior Report Independent Registered Public Accounting Firm
Reporting Accounting Changes Interim Financial Statements-an Amendment Apb Reporting Obligations
Reporting Outside Territory Reporting Territory
Reporting Violations Suspected Reports Trustee Holders
Representations Warranties Representations Warranties Certain Covenants Indemnification
Representations Warranties Parent Merger Sub Reprocessing
Repurchase Exercise Notice Fundamental Change Repurchase Option Holder Fundamental Change
Repurchases Common Stock Convertible Subordinated Notes Outstanding Request Application Trustee Take Action Indenture Shall Furnish
Require Additional Funds Require Additional Funds Not Know Available Terms Find
Research Development Research Development Expenditures
Research Development Expense Research Development Expenses
Research Development Programs Research Services
Reserves Right Amend Discontinue Plan Time Without Prior Resignation
Resin Investment Respiratory Syncytial Virus Rsv
Responding Government Requests Restricted Common Stock
Restricted Period Restricted Stock
Restricted Stock Unit Information Restriction Period
Restrictions Issue Shares Restrictions Payments
Restrictions Restriction Period Restrictive Agreements
Results 2004 Results 2005
Results Financial Operations Condition Results Operations Financial Condition
Retainers Retaliation
Retention Letter Retention Letters Executive Officers
Return Documents Revenue Arrangements Multiple Deliverables
Revenue Recognition Revenues
Revenues Generated Products Currently Market Successfully Develop Obtain Revision
Revision Classification Certain Securities Revocation Effect Consents
Revolving Credit Right Co-negotiation Chiron Hereby Grants Cubist Obtain Portion
Right Indemnification Right Indemnitee Bring Suit
Right Offer Right Redeem Notice Trustee
Right Sell Right Vote Proxies
Rights Rights Holders Receive Payment Convert
Rights Issued Respect Common Stock Rights Last Refusal Canada
Rights Negotiation Rights Option Stock Restricted
Rights Pending Lapse Risk Forfeiture Award Rights Trustee
Rights Trustee Paying Agent Risk Factors
Risk Forfeiture Risks Related Business
Rma Rna Interference Rnai
Role Compensation Consultant Role Management Compensation Determination Process
Rosenberg Royalty
Royalty Payments Reports Rrrrr Significant Market Event Means
Rsv Rsv Co-development Program Alnylam
Rsv02 Product Means Containing Alnylams Proprietary Composition Rules Construction
Rules Trustee Paying Agent Registrar Conversion Sale Shares
Sales Marketing Expense Sales Marketing Expenses
Sales Marketing Product Pricing Sales Milestone Payments
Sales Representatives Satisfaction Discharge Indenture
Savings Plan Savings Plan Other Defined Contribution Plans
Schedule Schedule 14a
Schedule Exchanges Notes Scientific Affairs Committee
Seal Searchable Text Graphics Shown Above
Sec Reports Secretary
Securities Exchange Act 1934 Securities Redeemed Part
Security Ownership Certain Beneficial Owners Management Security Ownership Certain Beneficial Owners Management Related Shareholder
Securityholder Lists See Accompanying Notes
Segment Information Selected Pathogens Complicated Skin Infections N122
Selected Pathogens Complicated Skin Invetions N122 Selected Quarterly Financial Data
Selection Registration Product Trademarks Selection Securities Redeemed
Selection Statutory Officers Separability
Sequence Licensed Product Including Composition Information Preclinical Clinical Series Convertible Preferred Stock
Series Redeemable Convertible Preferred Stock Serious Business
Service Revenues Settlement
Settlement Allocation Proceeds Severability
Several Aspects Corporate Governance Discourage Party Attempting Acquire Severance
Severance Benefits Shall Resume Payments Distributions Respect Securities Acquire Them
Share-based Payment Shares Available Issuance
Shares Subject Amended Restated Directors Plan Outstanding Awards Shares Subject Directors Plan Outstanding Awards
Shipping Shortcomings Current Antibacterial Therapies
Signature Signature Page Follows
Signatures Significant Balance Sheet Net Loss Improvement
Significant Customers Singleton
Soeters Source Hospital Antibiotic Market Guide Jan Dec 2004
Special Meeting Special Meetings
Specific Activities Addition Functions Described Jct Shall Particular Specific Business Policies
Specific Cubist Business Policies Specific Regulatory Activities Chiron Commercially Reasonable Efforts
Specification Review Committee Src Specifications
Sss Initial Sales Training Materials Meaning Ascribed Such Ssss Proceeding Meaning Ascribed Such Term 141
Sssss Significant Stockout Means Stability Program Batches
Stability Review Group Srg Staph Aureus
Staphylococcus Aureus Staphylococcus Aureus Mssa Mrsa
Statement Cash Flows Statements Contained Herein Not Historical Fact Forward-looking Within
Stay Extension Usury Laws Step
Sti Award Payout Process Stock
Stock Based Compensation Stock Compensation Expense Prior Adoption Sfas 123
Stock Issuances Stock Options
Stock Ownership Stock Ownership Guidelines
Stock Price Volatile Investment Decline Value Stock Price Volatile Value Decline
Stock-based Compensation Stock-compensation Expense Prior Adoption Fas 123
Stockholder Action Written Consent Stockholder Communications
Stockholder Proposals Stockholder Proposals Board Candidates
Stockholders Equity Stockholders List
Storage Storage Limit
Strictly Confidential Student Dies After Lengthy Illness
Study Study Completion Expected Mid-2005 149
Study Design Subcontracting
Sublicenses Transfers Chiron Technology Joint Rights Sublicensing Terms Liability
Submission Matters Vote Security Holders Subordinate Officers
Subordination Lilly Rights Subordination Not Impaired
Subrogation Subsequent Event
Subsequent Events Subsidiary
Substitute Committee Member Successful Commercialization Cubicin
Successor Substituted Successor Trustee Merger Etc
Successors Successors Assigns
Such Filings Statements Speak Only Date Release Undertake Such Term Used Describe Interest Rate Determination Respect
Suggested Forward-looking Statements Cubist Factors Include Not Limited Suite 1000-55
Suite 2200-55 Suite 3000-55
Suite 4600-45 Suites 2201-55 4201-55 4200-55
Summary Summary 1997 Employee Stock Purchase Plan
Summary Compensation Table Summary Employee Stock Purchase Plan
Summary Espp Summary Sfas 123 Expense
Summary Significant Accounting Policies Summary Stock Option Plans
Supply Obligations Alnylams Existing Manufacturing Arrangements Survival
Susceptibility Saureus Cubicin Table Contents
Tally Taphylococcus Aureus
Target Award Target Percentage
Tax Advice Tax Matters
Tax Treatment Taxes Conversion
Technology Manufacture Manufactured Licensed Products Development Commercialization Field Technology Transfer Exchange Know-how
Telephonic Participation Meetings Temporary Securities
Term Term Shall Mean Agreement
Term Termination Term Termination Amended Restated Directors Plan Amendment
Term Termination Directors Plan Amendment Term Termination Espp Amendment
Termination Termination Association
Termination Association Cubist Termination Certain Licensed Products
Termination Convenience Chiron Termination Either Party Bankruptcy Insolvency
Termination Employment Change-in-control Agreements Termination Employment Participating Employee
Termination Material Definitive Agreement Termination Rights
Terms Office Territory
Territory Specific Studies Testing Samples Release
Third-party Patent Intellectual Property Rights Interfere Ability Commercialize Time
Time Other Specified Following Clause 25000000 Tock
Total 2005 Quantity Total 2006 Quantity
Total 2007 Quantity Trade Cash Quantity Discounts Allowances Actually Allowed Taken
Trademark License Trademarks
Trademarks Current Future Modifications Variants Foregoing Rights Transactions Related Persons
Transcript Call Filed Sec Also Available Request Transfer Agent Registrar
Transfer Exchange Transfer Title
Transferability Awards Transferability Options
Transferred Materials Transfers Stock
Transition Manufacturing Responsibilities Cubist Treasurer
Treasury Securities Treatment Confidential Information
Trust Indenture Act Controls Trust Indenture Act Provisions
Trustee Trustee Act Through Agents Shall Not Responsible Misconduct
Trustee Not Relieved Liability Own Negligent Action Failure Trustee Proofs Claim
Trustee Sign Amendments Etc Trustees Disclaimer
Tty Biopharm Unable Adequately Protect Confidential Electronically Stored Transmitted Communicated
Unable Continue Develop Satisfactory Sales Marketing Capabilities Not Unable Discover Acquire Drug Candidates Not Able Implement
Unable Discover In-license Acquire Drug Candidates Not Able Unable Discover In-license Drug Candidates Develop Commercialize Products
Unable Generate Revenues Drug Products Other Cubicin Ability Unable Generate Revenues Expect Merrem Other Drug Candidates
Unable Maintain Satisfactory Sales Marketing Capabilities Not Continue Unable Maintain Satisfactory Sales Marketing Capabilities Not Succeed
Unable Pay Debts Receive Payment Convertible Notes Only Unable Repay Convertible Notes Due Repurchase Event
Undertake Additional Strategic Acquisitions Future Difficulties Integrating Such Undertake Additional Strategic Acquisitions Future Not Realize Benefits
Undertake Strategic Acquisitions Future Not Realize Benefits Such Undertaken Future Undertake Strategic Acquisitions Not Realize Benefits
Undertaking Costs Unforeseen Unanticipated Accounting Charges Treatments
United States Dollars Dollar Amounts Specified Agreement United States Means America Territories Possessions
Unlicensed Product Unregistered Sales Equity Securities
Unregistered Sales Equity Securities Proceeds Updated Tuesday 2005 1225
Upfront Consideration Us-fda Process
Usd 2000000 Usd 8500000
Uuu Initial Sales Training Program Meaning Ascribed Such Uuuu Product Incentive Compensation Meaning Ascribed Such Term
Vacancies Valid Claim
Validation Processing Related Services Valuation Assumptions
Value Value Received
Vancomycin Rising Clinical Failure Rates Vancomycin Sales
Vancomycin Still Preferred Antibiotic Empirical Coverage Definitive Therapy Variety Risks Associated International Business Relationships Materially Adversely
Vial Orders Continue Trend Upward Vialed Drug Product
Vice-presidents Vitro
Vivo Vote Important Please Immediately
Vote Required Vote Required Board Directors Recommendation
Vote Required Board Recommendation Vote Telephone Internet Available
Voting Voting Revocability Proxy
Voting Securities Owned Corporation Vre Vancomycin-resistant Enterococci
Vrsa Vancomycin-resistant Aureus Waiver
Waiver Defaults Events Default Waiver Jury Trial
Waivers Code Business Conduct Ethics Warrants
Washington 2005 Way Account Operational Business Activities Based Estimates Assumptions
Whats Next Whereas
Whether Food Drug Administration Fda Accepts Proposed Clinical Withholding
Withholding Notice Disposition Stock Prior Expiration Specified Holding Without Consent Holders
Witness Whereof Wood
Wwwcubistcom Wwwww Stockout Means
Xv- Term Termination Xxx
Xxxxx Sumitomo Means Pharmaceuticals Limited Successors Assigns Zzz Means Each Respective Successors Assigns
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki